Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AMC Entertainment

GameStop

This trio of companies has been unstoppable in 2021 -- but will they stay that way?

3 Stocks That Turned $250,000 Into $1 Million (or More) Since the Year Began

The biotech is seeking to cash in on the recent rally in its stock price.

Here's Why Ocugen Stock Rocketed 47% Today -- and Then Gave Up Almost All Its Gains

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering. The offering is expected to close on or about April 27, 2021, subject to the satisfaction of customary closing conditions.

Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

OCGN stock popped in February as investors anticipated revenue from a Covid-19 vaccine partnership. But with the U.S. looking to be well supplied, it's hard to see the opportunity.

Ocugen Looks Less Interesting With Each Passing Shot

OCGN stock soared on great news but it is now going into a prior failure level. Investors can hold it long term but short term, it's tricky.

Ocugen Stock Relief Pop Is Great, But It Needs More

OCGN stock is seeing upward momentum as it looks to become just the fourth vaccine option available in the U.S. The post OCGN Stock: The Big COVAXIN News That Prompted 40% Gains in Ocugen appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

OCGN Stock: The Big COVAXIN News That Prompted 40% Gains in Ocugen

Snap

Snap Inc (NYSE:SNAP) shares are trading higher by 4.5% in Friday's pre-market session after the company reported better-than-expected first-quarter sales results and issued second-quarter guidance. The company reported first-quarter daily active users of 280 million, up 22% year over year.

Here's Why Snap And Ocugen Are Popping Off Today

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 42.92%. This is why it happened.

OCGN Stock: 42.92% Increase Explanation

Ocugen Inc (NASDAQ: OCGN) shares soared 42.9% in the regular session and another 11% in the after-hours session on Thursday. What Happened: The shares surged following positive clinical data announced by a partner of Ocugen and a bullish stance taken by Roth Capital analyst Zegbeh Jallah who has a Buy rating on the stock and a 12-month price target of $10.

Why Ocugen Shares Skyrocketed Today

Analysts are growing more optimistic about the coronavirus vaccine maker's growth prospects.

Here's Why Ocugen Stock Skyrocketed Today

Nikola

Favorable news from two key sectors helped support the broader market.

Why Ocugen and Nikola Are Powering the Nasdaq Higher

Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.

Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate

Bharat Biotech says that its Covaxin demonstrated 100% efficacy against severe COVID-19.

Ocugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine

This small-cap biotech is currently trailing its rivals in the coronavirus vaccine race. Could a comeback be in the cards?

Could This Little-Known Company's Vaccine Candidate Leapfrog Moderna and Pfizer?

The shares of Ocugen Inc (NASDAQ: OCGN) have received a $10 price target by Roth Capital. These are the details.

OCGN Stock: $10 Target By Roth Capital

The biotech announced positive data for the coronavirus vaccine candidate it hopes to bring to the U.S. market.

Why Ocugen Stock Surged Today

Bionano Genomics

Ocugen Inc. (NASDAQ: OCGN) and Bionano Inc. (NASDAQ: BNGO) are two biopharma stocks moving higher Wednesday. Ocugen is moving after its partner Bharat Biotech announced positive study results, and Bionano gained ground after its system for optical genome mapping was adopted by two large labs in the U.K.'s National Health System.

2 Biopharma Stocks That Look Ready For A Bullish Reversal

Bionano Genomics, Inc. (NASDAQ: BNGO) and Ocugen, Inc. (NASDAQ: OCGN) were among the early movers among biopharma stocks. Bionano Gains On Adoption of Genomic Mapping System By U.K. Labs: Bionano said its Saphyr system for optical genome mapping has been adopted by two large labs belonging to the National Heath System of the U.K.

Why Bionano Genomics, Ocugen Are Rallying Today

OCGN stock is gaining Wednesday morning on news that Bharat Biotech's COVAXIN has an overall 78% efficacy rate. Here's what to know.

OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing Today

MALVERN, Pa., April 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of the second interim analysis of its Phase 3 study of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate. COVAXIN demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 78% with efficacy against severe COVID-19 disease alone of 100%.

Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 5% pre-market. This is why it happened.

OCGN Stock: Over 5% Increase Pre-Market Explanation

The U.S. is likely to receive enough vaccines from its current partners, so OCGN stock will probably tumble over the longer term. The post Ocugen's Outlook Is Still Very Bleak appeared first on InvestorPlace.

Ocugen's Outlook Is Still Very Bleak

India's Bharat Biotech has announced COVAXIN capacity expansion to support vaccination campaigns in India and globally amid increased COVID-19 infection cases. MoneyControl says that the capacity expansion has been implemented across multiple facilities in Hyderabad and Bangalore to reach over 700 million doses per year.

Ocugen's Partner Bharat Biotech Ramping Manufacturing To Produce 700M COVID-19 Vaccine Doses Annually

Humanigen

New coronavirus projects make them easy to hype, but they could face strong headwinds soon.

Reddit Traders Can't Get Enough of These 2 Resurgent Biotech Stocks

180 Life Sciences 

Citius Pharmaceuticals

Jaguar Health

Savara

Timber Pharmaceuticals

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

News for Ocugen, Inc. Stock (OCGN)